Filed
Pursuant to Rule 424b(3)
Registration
Statement No. 333-299686
PROSPECTUS
ARRIVE
AI INC.
1,665,382
shares of Common Stock, including 1,280,767 shares of Common Stock underlying a Common Stock Purchase Warrant
This
prospectus relates to the offer and resale, from time to time, by the selling stockholder identified herein (the “Selling Stockholder”)
of up to 1,665,382 shares of common stock, par value $0.0002 per share (the “Common Stock”), of Arrive AI Inc. (the “Company,”
“we,” “us” or “our”), consisting of (i) 384,615 shares of Common Stock (the “Shares”)
and (ii) up to 1,280,767 shares of Common Stock (the “Warrant Shares”) issuable upon exercise of a common stock purchase
warrant (the “Common Warrant”), which represents the maximum number of shares of Common Stock issuable upon exercise of the
Common Warrant on a cashless basis. The Shares and the Common Warrant were issued to the Selling Stockholder in a private placement (the
“Private Placement”) pursuant to that certain securities purchase agreement, dated October 5, 2026, between the Company and
the Selling Stockholder (the “Purchase Agreement”). The Common Warrant is immediately exercisable at an exercise price of
$0.70 per share and expires on October 5, 2031.
We
will not receive any proceeds from the sale of the shares of Common Stock by the Selling Stockholder. However, if the Common Warrant
is exercised in full for cash, we will receive gross proceeds of approximately $269,231. The Common Warrant may also be exercised on
a cashless basis, in which case we would not receive any cash proceeds. We cannot predict when, in what amounts or if the Common Warrant
will be exercised for cash, and it is possible that the Common Warrant may expire and never be exercised, in which case we would not
receive any cash proceeds.
The
Selling Stockholder may sell or otherwise dispose of the shares of Common Stock covered by this prospectus in a number of different ways
and at varying prices. We provide more information about how the Selling Stockholder may sell or otherwise dispose of the shares of Common
Stock covered by this prospectus in the section entitled “Plan of Distribution” on page 8. Discounts, concessions, commissions
and similar selling expenses attributable to the sale of shares of Common Stock covered by this prospectus will be borne by the Selling
Stockholder. We will pay all expenses (other than discounts, concessions, commissions and similar selling expenses) relating to the registration
of the shares of Common Stock with the Securities and Exchange Commission (the “SEC”).
Our
Common Stock is listed on The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “ARAI.” On October 26, 2026,
the last reported sale price of our Common Stock on Nasdaq was $0.11 per share.
Investing
in our securities involves significant risks. See “RISK FACTORS” on page 4 for information you should consider before buying
these securities.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
This
prospectus is not an offer to sell any securities in any state where the offer is not permitted.
The
date of this prospectus is November 16, 2026.
Prospective
investors may rely only on the information contained in this prospectus. We have not authorized anyone to provide prospective investors
with different or additional information. This prospectus is not an offer to sell nor is it seeking an offer to buy these securities
in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is correct only as of the
date of this prospectus, regardless of the time of the delivery of this prospectus or any sale of these securities.
TABLE
OF CONTENTS
| |
Page |
| IMPORTANT INFORMATION ABOUT THIS PROSPECTUS |
1 |
| CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION |
1 |
| SUMMARY OF THE OFFERING |
2 |
| ABOUT ARRIVE AI INC. |
3 |
| BUSINESS |
3 |
| RISK FACTORS |
4 |
| DESCRIPTION OF CAPITAL STOCK |
4 |
| USE OF PROCEEDS |
6 |
| PRIVATE PLACEMENT OF SHARES OF COMMON STOCK AND COMMON WARRANT |
6 |
| SELLING STOCKHOLDER |
7 |
| PLAN OF DISTRIBUTION |
8 |
| LEGAL MATTERS |
9 |
| EXPERTS |
9 |
| WHERE YOU CAN FIND MORE INFORMATION |
10 |
| INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE |
11 |
IMPORTANT
INFORMATION ABOUT THIS PROSPECTUS
This
prospectus relates to the resale by the Selling Stockholder identified in this prospectus under the caption “Selling Stockholder,”
from time to time, of up to 1,665,382 shares of Common Stock, consisting of 384,615 Shares and up to 1,280,767 Warrant Shares. We are
not selling any shares of Common Stock under this prospectus, and we will not receive any proceeds from the sale of shares of Common
Stock offered hereby by the Selling Stockholder, although we may receive cash from the exercise of the Common Warrant.
You
should rely only on the information provided in this prospectus. We have not authorized anyone to provide you with any other information
and we take no responsibility for, and can provide no assurances as to the reliability of, any other information that others may give
you. The information contained in this prospectus speaks only as of the date set forth on the cover page and may not reflect subsequent
changes in our business, financial condition, results of operations and prospects.
We
are not, and the Selling Stockholder is not, making offers to sell these securities in any jurisdiction in which an offer or solicitation
is not authorized or permitted or in which the person making such offer or solicitation is not qualified to do so or to any person to
whom it is unlawful to make such an offer or solicitation. You should read this prospectus in its entirety before making an investment
decision. You should also read and consider the information in the documents to which we have referred you in the section entitled “Where
You Can Find More Information” below, including the registration statement and the other reports we file with the SEC.
This
prospectus and any accompanying prospectus supplements may include trademarks, service marks and trade names owned by us or other companies.
All trademarks, service marks and trade names included in this prospectus or any accompanying prospectus supplement are the property
of their respective owners.
Unless
the context otherwise indicates, references in this prospectus to “we,” “us,” “our,” the “Company”
and “Arrive AI” refer to Arrive AI Inc., a Nevada corporation. The term “you” refers to a prospective investor.
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING INFORMATION
We
are making this statement pursuant to the safe harbor provisions for forward-looking statements described in the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are not historical facts but are the intent, belief, or current expectations of
our business and industry. We make statements in this prospectus, including statements that are incorporated by reference, that are forward-looking.
When used in this prospectus or in any other presentation, statements which are not historical in nature, including the words “anticipate,”
“estimate,” “could,” “should,” “may,” “plan,” “seek,” “expect,”
“believe,” “intend,” “target,” “project” and similar expressions are intended to identify
forward-looking statements. They also include statements regarding:
| |
● |
our
future growth and profitability; |
| |
● |
our
competitive strengths; and |
| |
● |
our
business strategy and the trends we anticipate in the industries and economies in which we operate. |
These
forward-looking statements are based on our current expectations and are subject to a number of risks, uncertainties and assumptions.
These statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are
beyond our control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted
in the forward-looking statements. Important factors that could cause actual results to differ materially from those in forward-looking
statements include:
| |
● |
economic
downturns, reduced capital expenditures, consolidation and technological and regulatory changes in our industry; |
| |
● |
the
highly competitive nature of our industry; |
| |
● |
our
ability to attract and retain qualified managers and skilled employees; |
| |
● |
the
outcome of our plans for future operations and growth; and |
| |
● |
the
other factors referenced in this prospectus, including, without limitation, under “Risk Factors.” |
We
believe these forward-looking statements are reasonable; however, you should not place undue reliance on any forward-looking statements,
which are based on current expectations. Furthermore, forward-looking statements speak only as of the date they are made. If any of these
risks or uncertainties materialize, or if any of our underlying assumptions are incorrect, our actual results may differ significantly
from the results that we express in or imply by any of our forward-looking statements. These and other risks are detailed in this prospectus,
in any supplements to this prospectus, in the documents that we incorporate by reference into this prospectus and in other documents
that we file with the SEC. We do not undertake any obligation to publicly update or revise these forward-looking statements after the
date of this prospectus to reflect future events or circumstances. We qualify any and all of our forward-looking statements by these
cautionary factors.
THE
OFFERING
| Shares
of Common Stock offered by the Selling Stockholder: |
|
Up
to 1,665,382 shares of Common Stock, consisting of (i) 384,615 Shares and (ii) up to 1,280,767 Warrant Shares issuable upon exercise
of the Common Warrant. |
| |
|
|
| Shares
of Common Stock outstanding prior to this offering (1): |
|
55,168,249
shares of Common Stock |
| |
|
|
| Shares
of Common Stock outstanding following to this offering (2): |
|
55,552,864
shares of Common Stock |
| |
|
|
| Use
of proceeds: |
|
We
will not receive any proceeds from the sale of the shares of Common Stock by the Selling Stockholder. However, we will receive gross
proceeds of approximately $269,231 if the Common Warrant is exercised in full for cash. We will not receive any proceeds upon a cashless
exercise of the Common Warrant. See “Use of Proceeds” on page 6 of this prospectus. |
| |
|
|
| Risk
factors: |
|
You
should read the “Risk Factors” section on page 4 of this prospectus for a discussion of factors to consider carefully
before deciding to invest in shares of our securities. |
| |
|
|
| Trading
symbol: |
|
Our
Common Stock is listed on Nasdaq under the symbol “ARAI.” There is no established trading market for the Common Warrant
and we do not expect a trading market to develop. |
(1)
The 55,168,249 shares of our Common Stock outstanding as of October 5, 2026 exclude the following:
| |
● |
4,756,529
shares of our Common Stock issuable upon the exercise of outstanding stock options and the vesting of outstanding restricted stock
units;] |
| |
|
|
| |
● |
82,237
shares of our Common Stock issuable upon exercise of outstanding warrants (other than the Common Warrant) having a weighted average
exercise price of $3.04; and |
| |
|
|
| |
● |
up
to 1,280,767 Warrant Shares issuable upon exercise of the Common Warrant (assuming exercise in full on a cashless basis). |
(2)
Assumes the issuance of all 1,280,767 Warrant Shares upon the exercise in full of the Common Warrant on a cashless basis, without regard
to any beneficial ownership limitations on exercise.
ABOUT
ARRIVE AI INC.
This
summary highlights selected information and does not contain all the information that is important to you. You should carefully read
this prospectus, any applicable prospectus supplement and the documents we have referred you to in “Incorporation of Certain Documents
by Reference” on page 11 of this prospectus for information about us and our financial statements as well as “Where You Can
Find More Information” on page 10.
Except
where the context otherwise requires, the terms “we,” “us,” “our,” “the Company,” or
“Arrive AI” refer to Arrive AI Inc.
BUSINESS
Company
Overview
Arrive
AI pioneered the smart mailbox for drone deliveries, evolving into a leader in the Autonomous Last Mile (“ALM”). Today, we
are transforming last-mile logistics by enabling secure, seamless exchanges between drones, robots, and people. Our mission is to connect
these systems through a universal ALM network of Arrive Points™-smart lockers and mini-cross-docks-powered by an AI-driven ALM
platform. This network unlocks exceptional efficiency, accelerating adoption in medical, retail, e-commerce, and beyond, making Arrive
AI the intelligent choice for the final inch of automated delivery.
Our
patented Arrive Points™ deliver a smart, secure, and seamless solution for automated last-mile delivery. These innovative docks
streamline exchanges by eliminating manual intervention and technical barriers, ensuring efficient data validation and synchronization.
With robust security, precise tracking, and support for diverse goods-including temperature-controlled options for food and medicine-Arrive
Points enhance chain of custody and product integrity. By bridging physical and digital interfaces, they are paving the way for scalable,
fully autonomous delivery networks.
We
expect to have three primary revenue streams:
1.
The Company is currently generating revenue through subscription services for Arrive Points, along with installation, support, and infrastructure
agreements with customers. We intend to provide our ALM access points to both businesses and consumers through monthly and annual subscription
fees. This turnkey service includes hardware, software, support, maintenance, installation/uninstallation, and financing for long-term
deployed assets. Our third-generation Arrive Points (“AP3” units), began revenue operation in 2025
2.
Data monetization via models and insights generated by machine learning and artificial intelligence (“ML” and “AI”).
Machine learning facilitates our systems’ ability to learn and improve from experience using data patterns, while artificial intelligence
encompasses broader capabilities and models to simulate human intelligence and decision-making. We plan to use both technologies distinctly:
a.
Machine learning: Primarily expected to be deployed in our fourth and fifth-generation Arrive Points (“AP4” and “AP5”
units) for local IoT (Internet of Things) data processing, edge computing (inferencing) for environment and transactional models, and
interactions models for drones and robots.
b.
Artificial intelligence: Used more broadly to analyze and derive insights from our network’s transactional and environmental data
through complex AI models, but we will also leverage foundational AI models like ChatGPT or LLaMa for device-based human interactions.
3.
Arrive Point Exchange. Our network of Arrive Points, the supporting software and AI plus ML, collectively create a platform that is intended
to provide valuable services and insights to all stakeholders in the ALM ecosystem. For example, our automated delivery marketplace (“ADM”)
will use a Google-AdSense-like market to help prioritize and optimize high-demand access schedules and space availability for our access
point network. This platform will provide a broad array of critical functions for the ALM ecosystem including arrival/departure scheduling,
space optimization, smart delivery notifications, micro weather conditions, local restrictions, transactional status updates, and automation
issues/obstacles. These advanced capabilities will be introduced in our AP5 development and pilot program currently in development.
We
differentiate ourselves through a comprehensive, integrated solution:
●
Universal Compatibility: Our multi-generational Arrive Points (AP3, AP4, AP5) are being developed for universal support of all drone
and robotic delivery systems, overcoming a major hurdle for widespread ALM adoption.
●
End-to-End Solution: We will combine advanced hardware with a powerful software platform and AI/ML capabilities, offering a complete
ecosystem for automated exchange.
●
Early Market Penetration: We have already secured pilot programs with significant customers, including a regional hospital and a specialty
pharmaceutical delivery company, demonstrating early validation and learning opportunities for sustainable economics.
Recent
Developments
Effective
October 27, 2026, the Company completed its conversion from a Delaware corporation to a Nevada corporation.
RISK
FACTORS
Investing
in our securities involves a high degree of risk. You should carefully consider the Risk Factors contained in our most recent annual
report on Form 10-K, filed with the U.S. Securities and Exchange Commission, as updated or supplemented by subsequent quarterly reports
on Form 10-Q and Current Reports on Form 8-K to the extent filed, each of which are incorporated herein by reference and in any supplement
to this prospectus before buying any offered securities, as the same may be updated from time to time by our future filings under the
Exchange Act.
DESCRIPTION
OF CAPITAL STOCK
The
following descriptions are summaries of the material terms of our certificate of incorporation and bylaws. Reference is made to the more
detailed provisions of, and the descriptions are qualified in their entirety by reference to, the certificate of incorporation and bylaws,
which have been publicly filed with the SEC. See “Where You Can Find More Information” and “Incorporation by Reference.”
General
Our
authorized capital stock consists of 500,000,000 shares of common stock, par value $0.0002 per share, of which 68,773,551 are issued
and outstanding as of October 26, 2026, after giving effect to the Reverse Stock Split retrospectively for all periods presented.
Common
Stock
The
Company’s common stock is quoted on Nasdaq under the symbol “ARAI”. As of October 26, 2026, there were approximately
3,477 stockholders of record of our common stock.
Preferred
Stock
Our
current certificate of incorporation does not authorize the issuance of preferred stock, and we have no preferred stock outstanding as
of the date of this prospectus.
Nevada
Anti-Takeover Law, Provisions of our Certificate of Incorporation and Bylaws
Anti-Takeover
Effects of Provisions of Nevada State Law
We
may be, or in the future we may become, subject to Nevada’s “acquisition of controlling interest statutes” (NRS 78.378
through 78.3793, inclusive). A corporation is subject to these “control share” laws if it has 200 or more stockholders of
record (at least 100 of whom have addresses in Nevada appearing on the corporation’s stock ledger at all times during the 90 days
immediately preceding the date of determination) and do business in the State of Nevada directly or through an affiliated corporation.
These control share laws may have the effect of discouraging corporate takeovers. As of October 28, 2026, we believe we have less than
100 stockholders of record who are residents of Nevada, and that these control share laws currently do not apply to us.
The
control share laws focus on the acquisition of a “controlling interest,” which means the ownership of outstanding voting
shares of an issuing corporation that would be sufficient, but for the operation of the control share laws, to enable the acquiring person
to exercise the following proportions of all of the voting power of the corporation in the election of directors: (1) one-fifth or more
but less than one-third; (2) one-third or more but less than a majority; or (3) a majority or more. The ability to exercise this voting
power may be direct or indirect, as well as individual or in association with others.
The
effect of the control share laws is that an acquiring person, and those acting in association with that person, will obtain only such
voting rights in the control shares as are conferred by a resolution of the stockholders of the corporation, approved by a majority of
the voting power of the corporation at a special or an annual meeting of stockholders. The control share laws do not expressly provide
a mechanism for stockholders to take away such voting rights from the control shares of an acquiring person once those rights have been
approved. If the stockholders do not grant voting rights to the control shares acquired by an acquiring person, those shares do not become
permanent non-voting shares. The acquiring person is free to sell the shares to others. If the buyer or buyers of those shares themselves
do not acquire a controlling interest, the shares are not governed by the control share laws.
If
control shares are accorded full voting rights and the acquiring person’s acquired control shares are entitled to exercise a majority
or more of the voting power in the election of directors, then a stockholder of record, other than the acquiring person, who did not
vote in favor of granting voting rights, is entitled to demand fair value for such stockholder’s shares.
In
addition to the control share laws, Nevada’s “combinations with interested stockholders” statutes (NRS 78.411 through
78.444, inclusive) prohibit certain business combinations between Nevada publicly traded corporations and “interested stockholders”
for two years after the interested stockholder first becomes an interested stockholder, unless the corporation’s board of directors
approved the combination or transaction before the person first became an interested stockholder. For purposes of Nevada law, an “interested
stockholder” is any person who is: (a) the beneficial owner, directly or indirectly, of 10% or more of the voting power of the
outstanding voting shares of the corporation, or (b) an affiliate or associate of the corporation and at any time within the previous
two years was the beneficial owner, directly or indirectly, of 10% or more of the voting power of the then-outstanding shares of the
corporation. A “combination”, as defined in NRS 78.416, includes, among other things, any merger or consolidation of the
corporation or any of the corporation’s subsidiaries with either (a) the interested stockholder or (b) any entity, whether or not
itself an interested stockholder of the corporation, which is, or after and as a result of the merger or consolidation would be, an affiliate
or associate of the interested stockholder. The definition of “combination” is sufficiently broad to cover virtually any
kind of transaction that would allow a potential acquirer to use the corporation’s assets to finance the acquisition or otherwise
to benefit its own interests rather than the interests of the corporation and its other stockholders.
The
effect of Nevada’s “business combinations” laws is to potentially discourage parties interested in taking control of
the Company from doing so if it cannot obtain the approval of our board of directors.
Articles
of Incorporation and Bylaws
Provisions
of our articles of incorporation and our bylaws may delay or discourage transactions involving an actual or potential change in our control
or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions
that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price
of our common stock. Among other things, our articles of incorporation and bylaws:
| |
● |
permit
our Board to issue up to 5,000,000 shares of preferred stock, without further action by the stockholders, with any rights, preferences
and privileges as our Board may designate, including the right to approve an acquisition or other change in control; |
| |
● |
provide
that the authorized number of directors may be changed only by a resolution adopted by a majority of the whole Board; |
| |
● |
provide
that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative
vote of a majority of directors then in office, even if less than a quorum; |
| |
● |
do
not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to
vote in any election of directors to elect all of the directors standing for election, if they should so choose); |
| |
● |
provide
that special meetings of our stockholders may be called only by (i) the Chairman of the Board, (ii) the Chief Executive Officer or
(iii) a resolution adopted by a majority of the whole Board; |
| |
● |
provide
that stockholders may alter, amend or repeal any section of our bylaws by an affirmative vote of the holders of at least sixty-six
and two-thirds (66 2/3%) of the outstanding voting power, voting together as a single class; and |
| |
● |
provide
advance notice provisions with which a stockholder who wishes to nominate a director or propose other business to be considered at
a stockholder meeting must comply. |
Special
meeting of stockholders
Our
bylaws further provide that special meetings of our stockholders may be called by the Chairman of the Board, upon written request of
the Board or the holders of a majority of the voting power of Arrive AI Inc.
Removal
of directors
Our
bylaws provide that a member of our Board may be removed from service as a director, with or without cause, only by the affirmative vote
of the holders of a majority of the shares of voting stock then outstanding and entitled to vote in an election of directors.
Limitation
of Liability and Indemnification of Directors and Officers
Our
bylaws provide that our directors and officers will be indemnified by us to the fullest extent authorized by Nevada law.
These
provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions
also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action,
if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder’s investment may be adversely affected
to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.
We believe that these provisions, insurance and the indemnity agreements are necessary to attract and retain talented and experienced
directors and officers.
We
are not aware of any threatened litigation or proceeding that might result in a claim for such indemnification, except as disclosed below.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling
persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification
is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
We
are currently engaged in legal proceedings which may require us to indemnify certain officers and directors if the outcome of either
proceeding is adverse to our interests. Please see the section titled “Legal Proceedings” in our Annual Report on
Form 10-K for the year ended December 31, 2025, incorporated by reference into this prospectus.
Listing
Our
common stock is currently listed on the Nasdaq Capital Market under the symbol “ARAI”.
Transfer
Agent and Registrar
The
transfer agent and registrar for our common stock is Odyssey Transfer and Trust Company. The transfer agent and registrar’s address
is 2155 Woodlane Drive, Suite 100, Woodbury, MN 55125. The transfer agent and registrar can be contacted by phone at: (612) 482-5100
or (888) 290-1175.
DESCRIPTION
OF WARRANTS
As
of October 5, 2026, we had outstanding warrants to purchase an aggregate of 82,237 shares of our Common Stock, with a weighted average
exercise price of $3.04 per share.(1)
| (1) |
This
amount does not include the Common Warrant issued in the Private Placement to purchase 384,615 shares of Common Stock at an exercise
price of $0.70 per share (or up to 1,280,767 Warrant Shares upon exercise in full on a cashless basis). |
USE
OF PROCEEDS
We
will not receive any proceeds from the sale of the shares of Common Stock by the Selling Stockholder. However, we will receive gross
proceeds of approximately $269,231 if the Common Warrant is exercised in full for cash. We will not receive any proceeds if the Common
Warrant is exercised on a cashless basis. We cannot predict when or if the Common Warrant will be exercised for cash, and it is possible
that the Common Warrant may expire and may never be exercised. We expect to use these proceeds, if any, for general working capital purposes.
PRIVATE
PLACEMENT OF SHARES OF COMMON STOCK AND COMMON WARRANT
On
October 5, 2026, the Company entered into the Purchase Agreement with the Selling Stockholder, an accredited investor, pursuant to which
the Company agreed to issue and sell to the Selling Stockholder, in a private placement in public equity transaction, (i) 384,615 Shares
and (ii) the Common Warrant to purchase 384,615 shares of Common Stock, for an aggregate purchase price of $250,000, or $0.65 per Share
and accompanying Common Warrant. The Private Placement closed on October 5, 2026 (the “Closing Date”).
We
received gross proceeds of $250,000 from the Private Placement, before deducting the $5,000 reimbursement of the Selling Stockholder’s
legal expenses and other offering expenses payable by us. No brokerage, finder’s fee or placement agent commission was payable
in connection with the Private Placement. We intend to use the net proceeds from the Private Placement for general working capital purposes.
The
Common Warrant is immediately exercisable at an exercise price of $0.70 per share and expires on October 5, 2031. The Common Warrant
may also be exercised, in whole or in part, on a cashless basis at any time during its term, in which case the holder is entitled to
receive a number of Warrant Shares equal to the number otherwise issuable upon exercise multiplied by 3.33, without payment of the exercise
price. Accordingly, the maximum number of Warrant Shares issuable upon exercise of the Common Warrant is 1,280,767 shares. The Common
Warrant generally may not be exercised to the extent the holder and its affiliates would beneficially own more than 4.99% of our outstanding
Common Stock immediately after exercise. The holder may increase or decrease this limitation, provided that it may not exceed 9.99%,
and any increase will not become effective until the 61st day after notice is delivered to us. The Warrant Shares are being registered
in this prospectus.
Under
the Purchase Agreement, the Company is required to file with the SEC, within 20 days after the Closing Date, a registration statement
on Form S-3 (or such other form as may then be available to the Company) covering the resale by the Selling Stockholder of the Shares
and the maximum number of Warrant Shares issuable upon exercise of the Common Warrant.
SELLING
STOCKHOLDER
The
Shares and the Common Warrant were issued to the Selling Stockholder in the Private Placement pursuant to the Purchase Agreement dated
October 5, 2026. Pursuant to the Purchase Agreement, we agreed to register for resale the Shares and the maximum number of Warrant Shares
issuable upon exercise of the Common Warrant. We are registering the Shares and the Warrant Shares in order to permit the Selling Stockholder
to offer such shares for resale from time to time.
The
table below lists the Selling Stockholder and other information regarding the beneficial ownership (as determined under Section 13(d)
of the Exchange Act, and the rules and regulations thereunder) of the shares of common stock held by the Selling Stockholder.
The
following table sets forth, based on information provided to us by or on behalf of the Selling Stockholder or known to us, the name of
the Selling Stockholder and the number of shares of our Common Stock beneficially owned by the Selling Stockholder before and after this
offering. The second column lists the number of shares of common stock beneficially owned by the Selling Stockholder, based on its ownership
of the shares of common stock and the Common Warrant, as of October 26, 2026, without regard to any limitations on exercise. The third
column lists the shares of Common Stock being offered by this prospectus by the Selling Stockholder. The fourth column assumes the sale
of all of the shares offered by the Selling Stockholder pursuant to this prospectus.
The
Selling Stockholder may sell all, some or none of their shares in this offering. See “Plan of Distribution.”
| Name of Selling Stockholder | |
Number of Shares of Common Stock Owned Prior to Offering(1) | | |
Maximum Number of shares of Common Stock to be Sold Pursuant to this Prospectus(2) | | |
Number of shares of Common Stock Owned After the Offering | |
| Growth Capital Partners, LLC (3) | |
| 1,665,382 | | |
| 1,665,382 | | |
| — | |
| (1) |
Consists
of 384,615 Shares and up to 1,280,767 Warrant Shares issuable upon exercise of the Common Warrant on a cashless basis. The Common
Warrant is subject to a beneficial ownership limitation of 4.99% (which may be increased to up to 9.99% upon 61 days’ notice
to us), which limitation has been disregarded for purposes of this table. |
| (2) |
Assumes
that the Selling Stockholder will sell all of the 1,665,382 shares of Common Stock offered pursuant to this prospectus. |
| (3) |
The
address of Growth Capital Partners, LLC is 2005 EAST 2700 SOUTH STE 200, Salt Lake City, UT, 84109. |
PLAN
OF DISTRIBUTION
The
Selling Stockholder and any of their pledges, assignees and successors-in-interest may, from time to time, sell any or all of their securities
covered hereby on the principal trading market or any other stock exchange, market or trading facility on which the securities are traded
or in private transactions. These sales may be at fixed or negotiated prices. The Selling Stockholder may use any one or more of the
following methods when selling securities:
| |
● |
ordinary
brokerage transactions and transactions in which the broker-dealer solicits purchasers; |
| |
|
|
| |
● |
block
trades in which the broker-dealer will attempt to sell the Shares as agent, but may position and resell a portion of the block as
principal to facilitate the transaction; |
| |
|
|
| |
● |
purchases
by a broker-dealer as principal and resale by the broker-dealer for its own account; |
| |
|
|
| |
● |
an
exchange distribution in accordance with the rules of the applicable exchange; |
| |
|
|
| |
● |
privately
negotiated transactions; |
| |
|
|
| |
● |
short
sales effected after the date the registration statement of which this prospectus is a part is declared effective by the SEC; |
| |
|
|
| |
●· |
through
the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; |
| |
|
|
| |
● |
through
agreements between broker-dealers and the seller stockholder(s) to sell a specified number of such Shares at a stipulated price per
share; |
| |
|
|
| |
● |
a
combination of any such methods of sale; and |
| |
|
|
| |
● |
any
other method permitted by applicable law. |
The
Selling Stockholder may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available,
rather than under this prospectus.
Broker-dealers
engaged by the Selling Stockholder may arrange for other broker-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the Selling Stockholder (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in
excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or
markdown in compliance with FINRA Rule 2121.
In
connection with the sale of the securities or interests therein, the Selling Stockholder may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the shares of Common Stock in the course of hedging the positions
they assume. The Selling Stockholder may also sell securities short and deliver these securities to close out their short positions,
or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholder may also enter into
option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require
the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
The
Selling Stockholder and any broker-dealers or agents that are involved in selling the Shares may be deemed to be “underwriters”
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the Shares purchased by them may be deemed to be underwriting commissions or discounts under
the Securities Act. The Selling Stockholder has informed us that they do not have any written or oral agreement or understanding, directly
or indirectly, with any person to distribute the securities.
We
agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholder
without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for
the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar
effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule
of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable
state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered
or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is
complied with.
Under
applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale Shares may not simultaneously
engage in market making activities with respect to the Common Stock for the applicable restricted period, as defined in Regulation M,
prior to the commencement of the distribution. In addition, the Selling Stockholder will be subject to applicable provisions of the Exchange
Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the Common
Stock by the Selling Stockholder or any other person. We will make copies of this prospectus available to the Selling Stockholder and
have informed it of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by
compliance with Rule 172 under the Securities Act).
LEGAL
MATTERS
Certain
legal matters with respect to the validity of the securities offered under this prospectus and any supplement hereto will be passed upon
for us by Lucosky Brookman LLP, 101 Wood Avenue South, 5th Floor, Woodbridge, NJ 08830. Counsel for any underwriter or agents will be
noted in the applicable prospectus supplement.
EXPERTS
The
financial statements of Arrive AI Inc. as of and for the year ended December 31, 2025, incorporated by reference in this prospectus and
elsewhere in this Registration Statement, have been audited by Stephano Slack LLC, an independent registered public accounting firm,
as set forth in their report, which contains an explanatory paragraph relating to substantial doubt about Arrive AI Inc.’s ability
to continue as a going concern, incorporated by reference herein, and have been so incorporated in reliance upon the report of such firm
given on their authority as experts in accounting and auditing.
The
financial statements of Arrive AI Inc. as of and for the year ended December 31, 2024, incorporated by reference in this prospectus and
elsewhere in this Registration Statement, have been audited by Assurance Dimensions LLC, an independent registered public accounting
firm, as set forth in their report, which contains an explanatory paragraph relating to substantial doubt about Arrive AI Inc.’s
ability to continue as a going concern, incorporated by reference herein, and have been so incorporated in reliance upon the report of
such firm given on their authority as experts in accounting and auditing.
Resignation
of Stephano Slack LLC
On
October 13, 2026, Stephano Slack resigned as the independent registered public accounting firm of the Company, effective October 13,
2026. The separation was amicable, and the Company and Stephano Slack intend to cooperate in facilitating an orderly transition to the
Company’s successor independent registered public accounting firm. The Audit Committee of the Board approved the change in the
Company’s independent registered public accounting firm. Stephano Slack’s report on the Company’s financial statements
as of and for the fiscal year ended December 31, 2025 did not contain an adverse opinion or disclaimer of opinion and was not qualified
or modified as to uncertainty, audit scope or accounting principles, except that such report included an explanatory paragraph regarding
substantial doubt about the Company’s ability to continue as a going concern. During the fiscal year ended December 31, 2025 and
the subsequent interim period through October 13, 2026, (i) there were no disagreements within the meaning of Item 304(a)(1)(iv) of Regulation
S-K between the Company and Stephano Slack on any matter of accounting principles or practices, financial statement disclosure, or auditing
scope or procedure, which disagreements, if not resolved to Stephano Slack’s satisfaction, would have caused Stephano Slack to
make reference to the subject matter of the disagreement in connection with its report, and (ii) there were no reportable events within
the meaning of Item 304(a)(1)(v) of Regulation S-K, except for the material weakness in the Company’s internal control over financial
reporting identified in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in the Company’s
Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026, relating to the accounting for embedded derivatives
in hybrid financial instruments and the accretion of discounts on host debt instruments, which material weakness had not been remediated
as of June 30, 2026, and which resulted in the Company filing amended Quarterly Reports on Form 10-Q/A for the quarters ended June 30,
2025 and September 30, 2025 to restate the financial statements included therein.
The
Company provided Stephano Slack with a copy of the foregoing disclosures and requested that Stephano Slack furnish a letter addressed
to the SEC stating whether it agrees with the statements made therein. A copy of Stephano Slack’s letter, dated October 16, 2026,
was filed as Exhibit 16.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 16, 2026.
Engagement
of M&K CPAS, PLLC
Effective
October 13, 2026, the Company engaged M&K CPAS, PLLC (“M&K”) as the Company’s new independent registered public
accounting firm to review the Company’s interim financial statements for the quarter ending September 30, 2026 and to audit the
Company’s financial statements for the fiscal year ending December 31, 2026. The engagement of M&K was approved by the Audit
Committee of the Board.
During
the fiscal years ended December 31, 2025 and December 31, 2024 and the subsequent interim period through October 13, 2026, neither the
Company nor anyone on its behalf consulted with M&K regarding (i) the application of accounting principles to a specified transaction,
either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither
a written report nor oral advice was provided to the Company that M&K concluded was an important factor considered by the Company
in reaching a decision as to any accounting, auditing or financial reporting issue, (ii) any matter that was the subject of a disagreement
within the meaning of Item 304(a)(1)(iv) of Regulation S-K, or (iii) any reportable event within the meaning of Item 304(a)(1)(v) of
Regulation S-K.
WHERE
YOU CAN FIND MORE INFORMATION
We
file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any documents
that we have filed with the SEC at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the
SEC at 1-800-SEC-0330 for further information on the public reference room. Our Securities and Exchange Commission filings are also available
to the public at the Securities and Exchange Commission’s website at http://www.sec.gov.
This
prospectus is part of a registration statement that we filed with the SEC. This prospectus and any subsequent prospectus supplements
do not contain all of the information in the registration statement as permitted by the rules and regulations of the SEC. You can obtain
a copy of the registration statement from the SEC’s website listed above.
INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE
The
SEC’s rules allow us to incorporate by reference information into this prospectus. This means that we can disclose important information
to you by referring you to another document. Any information referred to in this way is considered part of this prospectus from the date
we file that document. Any reports filed by us with the SEC after the date of this prospectus and before the date that the offering of
the securities by means of this prospectus is terminated will automatically update and, where applicable, supersede any information contained
in this prospectus or incorporated by reference in this prospectus.
We
incorporate by reference into this prospectus the following documents or information filed with the SEC (other than, in each case, documents
or information deemed to have been furnished and not filed in accordance with SEC rules):
| ● |
Our
Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on April 15, 2026; |
| |
|
| ● |
Our
Quarterly Report on Form 10-Q for three months ended June 30, 2025, filed with the SEC on August 14, 2025, as amended on April 15, 2026, our Quarterly Report on Form 10-Q for the three months ended September 30, 2025, filed with the SEC on November 14, 2025, as
amended, on April 15, 2026, our Quarterly Report on Form 10-Q for the three months ended March 31, 2026, filed with the SEC on May 15, 2026, and our Quarterly Report on Form 10-Q for the three months ended June 30, 2026, filed with the SEC on August 13, 2026; |
| |
|
| ● |
Our
Current Reports on Form 8-K filed with the SEC on January 30, 2026, April 3, 2026, April 14, 2026, April 28, 2026, May 18, 2026,
June 12, 2026, July 31, 2026, August 12, 2026, August 19, 2026, September 8, 2026, September 29, 2026, October 9, 2026, October 13, 2026, and October 16, 2026 (other than any portions thereof furnished and not filed, including information furnished under Item 2.02
or Item 7.01 and related exhibits); and |
| |
|
| ● |
The
description of our Common Stock contained in our registration statement on Form 8-A12B filed with the SEC on May 12, 2025, as amended
on May 13, 2025. |
Additionally,
all documents filed by us with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act, after (i) the date of the initial
Registration Statement and prior to effectiveness of the Registration Statement and (ii) the date of this prospectus and before the termination
or completion of this offering, shall be deemed to be incorporated by reference into this prospectus from the respective dates of filing
of such documents, except that we do not incorporate any document or portion of a document that is “furnished” to the SEC,
but not deemed “filed.” Any information that we subsequently file with the SEC that is incorporated by reference as described
above will automatically update and supersede any previous information that is part of this prospectus.
We
will provide without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon his or her written
or oral request, a copy of any or all documents referred to above that have been or may be incorporated by reference into this prospectus,
excluding exhibits to those documents unless they are specifically incorporated by reference into those documents. Written or telephone
requests should be directed to Arrive AI Inc., 9100 Fall View Drive Fishers, Indiana 46037, (463) 270-0092.
1,665,382
shares of Common Stock, including 1,280,767 shares of Common Stock underlying
a
Common Stock Purchase Warrant

ARRIVE
AI INC.
PROSPECTUS
November
16, 2026